We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 31

What to expect when you are expecting to launch a drug in Canada regulatory overview

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement

Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of

Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada

  • Bereskin & Parr LLP
  • -
  • Canada, Global
  • -
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Licensing basics for life sciences: getting paid through license fees

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • February 28 2013

In life sciences, licensing fees are often upfront payments, ongoing royalties (usually a percentage of net sales) or milestone payments after a

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc

Dosage regimens in Canada: patentable subject matter?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • April 10 2012

It is well known that methods of medical treatment do not constitute patentable subject matter in Canada